Shares of Clovis Oncology, Inc. (CLVS) approval of its lung cancer drug will be delayed since the U.S. Food and Drug Administration has asked for more information on the drug to analyze its effectiveness.
The Fly On The Wall
Cellectis analyst commentary
Cellectis UCART19 cells appear well tolerated in first use, says Piper Jaffray. Piper Jaffray analyst Joshua Schimmer said the early data released today suggest that Cellectis' UCART19 cells were well tolerated with no sign of GvHD reported in their first use in a human, "which is extremely important." and makes this " profilequite exciting," Schimmer wrote. The analyst reiterates his Overweight rating
Something wrong there.
all in baby!!!!